Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effi ...
Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...
A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...
1d
News Medical on MSNDo GLP-1 receptor agonists increase the risk of suicide in patients?A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...
Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results